Cited by 2,052Hepatocellular Carcinoma Treatment and PrognosisHepatitis B Virus StudiesHead and Neck Cancer Studies

The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Open access

Singal, Amit G., Llovet, Josep M., Yarchoan, Mark, Mehta, Neil, Heimbach, Julie K., Dawson, Laura A., Jou, Janice H., Kulik, Laura M., Agopian, Vatche G., Marrero, Jorge A., Mendiratta-Lala, Mishal, Brown, Daniel B., Rilling, William S., Goyal, Lipika, Wei, Alice C., Taddei, Tamar H.·2023·Hepatology

DOI 10.1097/hep.0000000000000466PMC PMC10663390

Open this paper in CoChat — free account Open PDF

Abstract

Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000000466

Cites

338 of 338 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“[309] mRECIST criteria has been proposed to adapt RECIST criteria to particularities of HCC, enabling capture of antitumoral response without observed shrinkage after local and systemic therapies.”
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
Influential
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · cited 1×
“[206] 211] The main barrier to LT is a shortage of available liver allografts compared with demand, prompting an allocation system that directs access to deceased donor organs for patients both with and without HCC.”
Hepatocellular carcinoma
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citation
Cancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 6,308
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“[320] In 2018, lenvatinib (an oral mTKI targeting vascular endothelial growth factor [VEGF]2 and other kinases) met its primary endpoint of noninferiority versus sorafenib in a global phase III randomized study, REFLECT.”

Show all 341 references

Research works printed but not linked: 2

Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057

Sorted by citations

Items 501–600 of 1,000

Navigating the Therapeutic Pathway and Optimal First-Line Systemic Therapy for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
Shin, H. P., & Lee, M. (2025) · Medicina · doi:10.3390/medicina61122164 · Cited by 6
“Systemic therapies with atezolizumab plus bevacizumab or durvalumab plus tremeli-mumab have been recognized as preferred first-line treatment options by several recent guidelines [6,59].”
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria
Fortuny, M., Rosa, A. D., Roca, I., Ouchi, D., Suárez, E., Cadiz, A., Matute‐González, M., Moon, A. M., Rimola, J., Torres, F., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001630 · Cited by 6
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials
Ascari, S., Chen, R., Sinno, A. D., Stefanini, B., Cescon, M., Serenari, M., Mosconi, C., & Tovoli, F. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i3.111528 · Cited by 6
“International guidelines recommend second-line mTKIs following progression on immunotherapy[27,28].”
Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma
Kim, N. G., Yao, F. Y. K., Kwong, A. J., & Mehta, N. J. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.01.008 · Cited by 6
Self-citation
Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma
Aceituno, L., Magyar, C. T. J., Tabrizian, P., Marino, R., Watt, K., Chascsa, D. M. H., Schnickel, G. T., Banz, V. M., Alconchel, F., Martagón, C., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70528 · Cited by 6
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
Matono, T., Tada, T., Hiraoka, A., Hirooka, M., Nakamura, Y., Yoshida, O., Kariyama, K., Nouso, K., Tani, J., Morishita, A., et al. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70422 · Cited by 6
Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma
Jeong, J. H., Hong, J. Y., Kim, D. Y., Lee, J. S., Kim, M. N., Kim, S. U., Kim, B. K., Park, J. Y., Kim, D. J., Ahn, S. H., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70850 · Cited by 6
Predicting the risk of early bleeding following endoscopic variceal ligation in cirrhotic patients with computed tomography
Ryu, H., Kim, T. U., Yoon, K. T., & Hong, Y. M. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-03038-1 · Cited by 6
“Patients with cirrhosis sometimes undergo CT scans to screen for HCC when ultrasound surveillance is suboptimal [33, 34].”
Background
Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study
Cheon, J., Jung, S., Kim, J. S., Kang, B., Kim, H., Chan, L. L., Becker, L., Gaillard, V. E., Chan, S. L., Kim, C., et al. (2024) · Liver International · doi:10.1111/liv.15935 · Cited by 6
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort Study
Abdelmalak, J., Strasser, S. I., Ngu, N. L., Dennis, C. V., Sinclair, M. J., Majumdar, A., Collins, K., Bateman, K., Dev, A. T., Abasszade, J. H., et al. (2024) · Cancers · doi:10.3390/cancers16111966 · Cited by 6
“The BCLC treatment algorithm recommends upfront ablation as the locoregional curative treatment choice for BCLC 0/A patients [19], and none of the major international or Australian guidelines recommend TACE as initial therapy in BCLC 0 or A disease [6,20–22].”
Method
Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies
Yelsangikar, A., & Patil, P. S. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101474 · Cited by 6
Microwave ablation followed by cTACE in 5-cm HCC lesions: does a single-session approach affect liver function?
Floridi, C., Cacioppa, L. M., Rossini, N., Macchini, M., Bruno, A., Agostini, A., Consoli, V., Inchingolo, R., Acquafredda, F., Nicolini, D., et al. (2024) · La radiologia medica · doi:10.1007/s11547-024-01842-7 · Cited by 6
Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents
Yoon, J. K., Han, D. H., Lee, S., Choi, J., Choi, G. H., Kim, D. Y., & Kim, M. (2024) · Liver International · doi:10.1111/liv.16059 · Cited by 6
Embolic and Ablative Therapy for Hepatocellular Carcinoma
Khalid, M., Likhitsup, A., & Parikh, N. D. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.003 · Cited by 6
Correlation of Needle Biopsy–Acquired Histopathologic Grade of Hepatocellular Carcinoma with Outcomes after Thermal Ablation
Chiang, J., Raman, S. S., Ramakrishnan, A., Keshavarz, P., Sayre, J. W., McWilliams, J. P., Finn, R. S., Agopian, V. G., Choi, G., & Lu, D. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.09.008 · Cited by 6
Self-citation
Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis
Abedrabbo, N., Lerner, E., Lam, E., Kadi, D., Dawit, H., van der Pol, C. B., Salameh, J., Naringrekar, H., Adamo, R. G., Alabousi, M., et al. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04580-6 · Cited by 6
“The choice of treatment is contingent upon several factors including tumor burden, liver function, and patient performance status [25].”
Self-citation
Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
Tomonari, T., Tani, J., Sato, Y., Tanaka, H., Morishita, A., Okamoto, K., Kawano, Y., Sogabe, M., Miyamoto, H., & Takayama, T. (2024) · JGH Open · doi:10.1002/jgh3.70033 · Cited by 6
“6 Thus, Dur + Tre is recommended as a ﬁ rst-line option for patients at risk of bleeding.”
Background
The Changing Face of Hepatitis Delta Virus Associated Hepatocellular Carcinoma
Cardoso, M. F., & Machado, M. V. (2024) · Cancers · doi:10.3390/cancers16223723 · Cited by 6
“…European and American guidelines recommend HCC surveillance when the annual risk is at least 0.2%, corresponding to the intermediate and high-risk groups in PAGE-B score for HBV mono-infected patients [94,95]. be made to diagnose tumors that still fulfill the criteria for liver transplantation.”
Influential
Tumor Seeding With Needle Biopsy of Hepatocellular Carcinoma: A Systematic Review
Nie, C., Vaska, M. M., Wong, J. K., Bathe, O. F., Przybojewski, S. J., Burak, K. W., Tang, P. A., & Congly, S. E. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003210 · Cited by 6
“It must be additionally noted that sensitivity of liver biopsy has been quoted between 70% and 93%, but has been reported as low as 60% in tumors , 2 cm (particularly given a decreased density of tumor vessels in early HCC), necessitating follow-up imaging and potentially a second biopsy (10).”
Liver elastography-based risk score for predicting hepatocellular carcinoma risk
Tian, C., Ye, C., Guo, H., Lu, K., Yang, J., Wang, X., Ge, X., Yu, C., Lu, J., Jiang, L., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae304 · Cited by 6
Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults
Cong, X., Song, S., Li, Y., Song, K., MacLeod, C., Cheng, Y., Lv, J., Yu, C., Sun, D., Pei, P., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03754-9 · Cited by 6
A facile combined therapy of chemotherapeutic agent and microRNA for hepatocellular carcinoma using non-cationic nanogel
Zhang, D., Zuo, M., Zhou, J., Ouyang, S., Liu, S., Yuan, J., Ou, C., Chen, Q., Yu, D., Cheng, D., et al. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02256d · Cited by 6
Grading risk of microvascular invasion impacts survival in hepatocellular carcinoma patients undergoing adjuvant transarterial chemoembolization: A multicenter study
Lu, J., Feng, J.-K., Zhao, Y., Chen, B., Li, P., He, C., Gong, L., & Bao, L.-L. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110102 · Cited by 6
Comparison of the GALAD, GAAP, and ASAP Scores for Hepatocellular Carcinoma Detection in Patients With Chronic Liver Diseases
Thanapirom, K., Suksawatamnuay, S., Thaimai, P. M., Siripon, N., Geratikornsupuk, N., Treeprasertsuk, S., & Komolmit, P. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102607 · Cited by 6
Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B
Saeoui, T., Kositamongkol, C., Chantrakul, R., Sripongpun, P., Chamroonkul, N., Kongkamol, C., Phisalprapa, P., & Kaewdech, A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70386 · Cited by 6
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction
Muñoz, S., Sapena, V., García‐Criado, Á., Darnell, A., Forner, A., Belmonte, E., Sanduzzi‐Zamparelli, M., Rimola, J., Soler, A., Llarch, N., et al. (2023) · Cancers · doi:10.3390/cancers15133269 · Cited by 6
Assessment of STAT4 Variants and Risk of Hepatocellular Carcinoma in Latin Americans and Europeans
Ayoub, A., Anugwom, C. M., Prieto, J. E., Balderramo, D. C., Ferrer, J. D., de Mattos, Â. Z., Arrese, M. A., Carrera, E., Groothuismink, Z. M. A., Oliveira, J., et al. (2023) · Cancers · doi:10.3390/cancers15184530 · Cited by 6
“Patients were classified as having HCC if they met the American Association for the Study of Liver Disease’s prescribed biopsy or imaging standards [26].”
Method
From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.
Piñero, F., Mauro, E., Casciato, P. C., & Forner, A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101185 · Cited by 6
Health-related quality of life in Thai patients with chronic hepatitis B
Chantrakul, R., Sripongpun, P., Pattarapuntakul, T., Chamroonkul, N., Kongkamol, C., Phisalprapa, P., & Kaewdech, A. (2023) · Gastroenterology report · doi:10.1093/gastro/goae015 · Cited by 6
Hepatocellular carcinoma
Gaillard, F., Silverstone, L., & Campos, A. (2008) · Radiopaedia.org · doi:10.53347/rid-1442 · Cited by 6
Can Dynamic Contrast-Enhanced MRI Be Used to Differentiate Hepatic Hemangioma from Other Lesions in Early Infancy?
Halevy, D., Sayed, B. A., Shaikh, F., Siddiqui, I. F. S., & Chavhan, G. B. (2024) · Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging · doi:10.1055/s-0044-1785208 · Cited by 5
“11 Role of MRI in detection, characterization, and assessment of staging and extent in hepatic lesions is also well described in children.”
Background
Prognostic Role of Basal Serum Alpha-Fetoprotein in Patients with Hepatocellular Carcinoma Suitable for Curative Treatment
Mazza, S., Frigerio, C., Alfieri, D., Mauro, A., Viera, F. T., Scalvini, D., Barteselli, C., Sgarlata, C. S., Veronese, L., Bardone, M., et al. (2024) · Medicina · doi:10.3390/medicina60050692 · Cited by 5
“Such a high incidence of HCC in cirrhotic patients supports the implementation of surveillance programs, with a 6-month surveillance with abdominal ultrasound being recommended by European and American guidelines [7,8].”
Background
Circulating microRNA-21, microRNA-122, and microRNA-222 as diagnostic biomarkers for hepatitis c virus-related hepatocellular carcinoma
Hetta, ‏. F., Hamed, H. M., Mekky, M. A., Abdelmalek, M. O., & Hassan, W. A. (2024) · Egyptian Liver Journal · doi:10.1186/s43066-024-00385-w · Cited by 5
“[5] The intense need for more reliable, sensitive and non-invasive biomarkers utilizes many genetic and molecular tools.”
Community-Based Point-of-Care Screening for Hepatitis B Virus and Hepatocellular Carcinoma in Rural Tanzania
Tappata, M., Ford, J. S., Kayandabila, J., Morrison, J., Seth, S., Lyimo, B., May, L. S., & Debes, J. D. (2025) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.24-0341 · Cited by 5
Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis
Schulze, K., Rose, T. D., Adlung, L., Peschka, M., Pagani, F., Gorgulho, J., Fründt, T., Labgaa, I., Haber, P. K., Zimpel, C., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101340 · Cited by 5
Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk
Fassio, E., Colombato, L., Gualano, G., Perez, S., Puga‐Tejada, M., & Landeira, G. (2025) · Cancers · doi:10.3390/cancers17061018 · Cited by 5
“…the Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma by the American Association for the Study of Liver Diseases states that “HCC incidence is significantly lower in post-SVR patients without cirrhosis, and surveillance is not cost-effective or recommended in this population” [25].”
Advances in radiation therapy for HCC: Integration with liver-directed treatments
Yariv, O., Newman, N. B., Yarchoan, M. M., Rabiee, A., Wood, B. J., Salem, R., Hernandez, J. M., Bang, C. K., Yanagihara, T. K., & Escorcia, F. E. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000653 · Cited by 5
“Emerging evidence supporting the efficacy of EBRT for patients with early or intermediate HCC prompted its inclusion in clinical guidelines (eg, National Comprehensive Cancer Network [NCCN], [13] American Association for the Study of Liver Diseases [AASLD] [14] ).”
Self-citation
Role of imaging-guided biopsy for hepatocellular carcinoma
Cannella, R., Berman, Z. T., Tirukkovalur, N. V., Tohme, S. T., Minervini, M. I., & Furlan, A. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112271 · Cited by 6
Combination of modified albumin-bilirubin grade and platelet count to predict high-risk varices in patients with hepatocellular carcinoma
Ananchuensook, P., Piyawannasuth, K., Suksawatamnuay, S., Thaimai, P. M., Siripon, N., Sriphoosanaphan, S., Thanapirom, K., & Komolmit, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0327967 · Cited by 5
“According to the American Association for the Study of Liver Disease guidelines, HCC is diagnosed histopathologically or by a compatible arterial enhancing liver mass with rapid venous washout on contrast-enhanced abdominal imaging in patients with chronic liver disease or cirrhosis [19].”
Emerging Role of MRI ‐Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review
Che, F., Zhu, J., Li, Q., Jiang, H., Wei, Y., & Song, B. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70048 · Cited by 6
“Systemic therapy is recommended for patients with unresectable HCC who are ineligible for curative or locoregional treatments, including those with advanced disease (BCLC C), selected intermediate-stage cases (BCLC B), or progression after LRTs [80].”
Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation
Parikh, N. D., Patel, R. A., Hu, J., Stirnadel-Farrant, H. A., Kebede, N., Wang, C., & Garcia-Reyes, K. (2025) · Hepatic Oncology · doi:10.1080/20450923.2025.2530377 · Cited by 5
“For patients with unresectable eHCC, liver transplantation is associated with the best outcomes; however, graft availability and recipient eligibility are barriers to transplantation [5].”
Influential
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
Vitale, A., Kim, J. S., Cabibbo, G., Gardini, A. C., Iavarone, M. A., Rimassa, L., Ponziani, F. R., Tovoli, F., Chon, H. J., Kang, B., et al. (2025) · Liver Cancer · doi:10.1159/000547792 · Cited by 5
“…with HCC have access to several treatment options, including liver transplantation (LT), liver resection (LR), thermal ablation (TA), intra-arterial therapies, such as trans-arterial chemo-embolisation (TACE) or radioembolisation (TARE), external radiotherapy, and systemic therapies (STs) [5–7].”
What we missed then, AI sees now: Revisiting legacy large extracellular vesicle data to reveal synergistic biomarkers for liver cancer screening
Willms, A. G., Krawczyk, M. J., Julich‐Haertel, H., Gries, S. K., Bañales, J. M., Mocan, T., Klein, A., Schaaf, S., Güsgen, C., Schwab, R., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101540 · Cited by 5
Induced Pluripotent Stem Cell-Based Cancer Immunotherapy: Strategies and Perspectives
Xun, X., Hao, J., Cheng, Q., & Gao, P. (2025) · Biomedicines · doi:10.3390/biomedicines13082012 · Cited by 5
Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
Sugimoto, R., Kurokawa, M., Tanaka, Y., Senju, T., Kohjima, M., & Tanaka, M. (2025) · Current Oncology · doi:10.3390/curroncol32090490 · Cited by 5
“However, with the advent of nucleoside analogues that can cure hepatitis C, the underlying risk factors for HCC have altered, shifting the primary cause of carcinogenesis from viral hepatitis to metabolic dysfunction-associated steatohepatitis, including non-alcoholic steatohepatitis [2].”
MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression
Asero, C., Franzè, M. S., Cacciola, I., & Gangemi, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178633 · Cited by 6
“MASLD can progressively evolve into metabolic dysfunction-associated steatohepatitis (MASH), characterized by hepatocellular ballooning and lobular inflammation, but also into liver cirrhosis and hepatocellular carcinoma (HCC) [18,19].”
The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT
Gong, H., Cheng, Y., Li, Q., He, Y., Cai, Q., Tang, Y., Liu, Y., Kuang, L., Li, Y., Shang, J., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07548-w · Cited by 5
“Inclusion criteria: (a) age > 18 years; (b) diagnosed with HCC by clinicians based on pathology or clinical diagnostic criteria [ 5]; (c) diagnosed with uHCC by hepatobiliary surgeons based on the patient’s lesion characteristics, invasion and metastasis, liver reserve function, physical status,…”
Influential
Role of ALBI Grade as a Predictive Factor for Long‐Term Mortality in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Ko, K. A., Oh, H., Kim, M. S., Hong, H. P., Cho, Y. K., Kim, B. I., & Sohn, W. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70098 · Cited by 5
Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions
Parraga, X., Razzak, I. A., Chumdermpadetsuk, R. R., Alsaqa, M., Lingamsetty, S. S. P., Bonder, A., & Saberi, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197009 · Cited by 5
“For patients with early-stage HCC who are not candidates for resection due to liver dysfunction or multifocal tumors, liver transplant (LT) offers a curative option for both the cancer and the underlying liver disease [2].”
CT-Based Habitat Model for Predicting Tumor Response and Survival in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors
Shen, X., Zhang, J.-X., Yan, H., Liu, J., Liu, S., Shi, H.-B., & Zu, Q. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.09.022 · Cited by 5
Reactivation of the PI3K/mTOR Signaling Pathway Confers Resistance to the FGFR4 Inhibitor FGF401
Huynh, H. T., & Ng, W. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199818 · Cited by 5
“Systemic therapies combining atezolizumab and bevacizumab or durval-umab and tremelimumab are now the preferred first-line option [2], except in patients with high-risk stigmata of varices, gastrointestinal bleeding or advanced liver cirrhosis [16].”
Long-Term Survival and Beneficiaries of Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Guo, B., Luo, C., Lu, Y., Wu, Y., Xie, S., Xia, F., Hua, Y., Zhu, J., Cai, G., Zhu, H., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18549-2 · Cited by 6
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma
Maesaka, K., Hikita, H., Tahata, Y., Nishioka, C., Kai, M., Shirai, K., Murai, K., Makino, Y., Saito, Y., Kodama, T., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02308-x · Cited by 5
Chemoprevention of hepatocellular carcinoma
Schwenk, S., & Kaplan, D. E. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000836 · Cited by 6
“[ 2 ] ANTIHYPERTENSIVE AGENTS Antihypertensive medications, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and non-selective beta blockers (NSBBs), have been studied in relation to HCC chemoprevention in patients with liver disease.”
Influential
Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)
Ioannou, G. N., Taddei, T. H., Planeta, B. M., Huang, G. D., Weiss, N. S., Morgan, T. R. M., Dominitz, J. A., Abou‐Alfa, G. K., Bashir, M. R., Beheshti, M. V., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101666 · Cited by 5
Self-citation
TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study
Yin, L., Li, W., Shao, W., Hou, X., Liu, B., Liu, X., Liu, R., & Huang, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1669856 · Cited by 6
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B
Sasaki, R., Shimose, S., Saeki, I., Ito, T., Takeuchi, Y., Tani, J., Tomonari, T., Sasaki, K., Kakizaki, S., Hatanaka, T., et al. (2025) · Liver International · doi:10.1111/liv.70466 · Cited by 5
Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
Kumada, T., Toyoda, H., Yasuda, S., Koshiyama, Y., Ito, T., Akita, T., & Tanaka, J. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70483 · Cited by 5
“Less than the lower limit of quantification, HBV RNA 10 copies/mL. patients based on traditional risk factors [24, 25].”
Comparison of Annual Dynamic Abbreviated MRI and Biannual Ultrasound for HCC Surveillance in a High-Risk Group: Two-Center Cohort Study
Yoon, J. H., Choi, J.-I., Yoo, J., Jeon, S. K., Kim, J. H., Bae, J. S., Kang, H.-J., Kim, H., Youn, S. Y., Kim, D. H., et al. (2025) · Liver Cancer · doi:10.1159/000548516 · Cited by 5
Care for Vulnerable Populations with Chronic Liver Disease: A Safety-Net Perspective
Wang, M. C., Bangaru, S. D., & Zhou, K. (2023) · Healthcare · doi:10.3390/healthcare11202725 · Cited by 5
“There are suboptimal rates of guideline-concordant screening and surveillance for HCC (ultrasound and alpha-fetoprotein every 6 months) in the US for all cirrhotics, but they are lowest in those of a lower socioeconomic status [30].”
Background
Prognostic Factors for Mortality in Hepatocellular Carcinoma at Diagnosis: Development of a Predictive Model Using Artificial Intelligence
Martínez-Blanco, P., Suárez, M., Gil-Rojas, S., Torres, A., Martínez-García, N., Blasco, P., Torralba, M., & Mateo, J. (2024) · Diagnostics · doi:10.3390/diagnostics14040406 · Cited by 5
“However, factors such as MASLD and alcohol consumption continue to be determining factors in the development of ACLD and HCC, with an increasing incidence in recent years, particularly in Western countries [3,37].”
BackgroundInfluential
Compared with SonoVue® LR-5, Sonazoid® modified LR-5 has better diagnostic sensitivity for hepatocellular carcinoma: a systematic review and meta-analysis
Cao, J., Wang, H., & Ling, W. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-1616 · Cited by 5
“As a radiation-free, real-time, and cost-effective imaging modality, contrast-enhanced ultrasound (CEUS) has been recommended for the screening of high-risk populations and has been shown to exhibit good diagnostic performance in diagnosing HCC (3,4).”
Background
Statins in Chronic Liver Disease: Review of the Literature and Future Role
Pham, N., & Benhammou, J. N. (2024) · Seminars in Liver Disease · doi:10.1055/a-2319-0694 · Cited by 5
“166 169 The lack of complete responses to new ﬁ rst-line agents, decrease in liver transplantation in patients with HCC due to recent UNOS policy changes, and rise in MASLD-HCC as an indication for liver transplantation have made identifying chemoprevention agents and treatments more relevant than…”
Background
Clinical Utility of the aMAP Score for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
Chaiwiriyawong, S., Assawasuwannakit, S., Feuangwattana, P., Sripongpun, P., Chamroonkul, N., Piratvisuth, T., & Kaewdech, A. (2024) · Diagnostics · doi:10.3390/diagnostics14131325 · Cited by 5
Machine learning model based on dynamic contrast-enhanced ultrasound assisting LI-RADS diagnosis of HCC: A multicenter diagnostic study
Xiao, M., Deng, Y., Zheng, W., Huang, L., Wang, W., Yang, H., Gao, D., Guo, Z., Wang, J., Li, C., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38850 · Cited by 5
“Therefore, the imaging diagnosis of HCC is particularly important [13,14].”
Background
Combining CEUS and CT/MRI LI-RADS major imaging features: diagnostic accuracy for classification of indeterminate liver observations in patients at risk for HCC
Xiao, T. S., Kuon-Yeng, C., Tahmasebi, A., Kono, Y., Piscaglia, F., Wilson, S. R., Medellin, A., Rodgers, S. K., Planz, V. B., Kamaya, A., et al. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04625-w · Cited by 5
“The most common being hepatocellular carcinoma (HCC), comprising more than 80% of cases [2].”
Risk of Hepatocellular Carcinoma in Subcentimeter Liver Nodules Identified on Surveillance Ultrasound: A Systematic Review
Koo, E., Dahan, K. S. E., Daher, D., Rich, N. E., Mittal, S., Yang, J. D., Parikh, N. D., & Singal, A. G. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.08.051 · Cited by 5
Self-citation
Shattering the monolith: burden of gastrointestinal cancer in Asian Americans, Native Hawaiians, and Pacific Islanders in the United States
Yoon, J. Y., Shah, S. C., Lin, J. J., Kim, M. K., Itzkowitz, S. H., & Wang, C. P. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100954 · Cited by 5
“21 Within the US, the aetiology of HCC varies by origin group, where targeted disease surveillance and screening should be considered.”
Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma
Zheng, Z., Guan, R., Zhao, R., Gan, J., Xiong, X., Zou, J., Li, S., Wang, Q., Wei, W., Mei, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1496095 · Cited by 5
“…are: 1) diagnosed by imaging examinations or biopsy pathology based on American Association for the Study of Liver Diseases (AASLD) guidelines (16); 2) aged between 18 to 80 years; 3) had treated with at least one locoregional therapy and 2 cycles immunotherapy; 4) had a performance status…”
Persisting challenges in the early detection of hepatocellular carcinoma
Arvind, A., Redmon, K., & Singal, A. G. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2467184 · Cited by 5
“Both the AASLD and the American College of Radiology suggest obtaining a follow-up surveillance CT or MRI in patients with severe visualization limitations on ultrasound [13,53].”
Self-citation
Theranostic radionuclides labeled biodegradable microspheres for the treatment of hepatocellular carcinoma with radioembolization
Pang, F., Deng, H., Peng, D., He, J., Zhao, W., Yu, L., Chen, T., Zonggui, X., Cai, H., & Chen, B. (2025) · Radiation Physics and Chemistry · doi:10.1016/j.radphyschem.2025.112642 · Cited by 5
Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients
Saborido, B., Darnell, A., Forner, A., García‐Criado, Á., Díaz, A., Ayuso, C., Vilana, R., Bruix, J., Reig, M., & Rimola, J. (2025) · European Radiology · doi:10.1007/s00330-025-11495-3 · Cited by 5
Efficacy and Safety of Ipilimumab Plus Anti-PD-1/PD-L1 Antibodies Combination Therapy in Advanced Hepatocellular Carcinoma Patients Progressing After Multiple Lines of Treatment: A Retrospective Multicenter Study
Zheng, S.-S., Wu, J., Zhang, Z., Wu, Y., Chen, Y., Qian, S., & Zhang, B. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s512302 · Cited by 5
US Liver Imaging Reporting and Data System Version 2017: A Systematic Review and Meta-Analysis
Lee, S., Yoon, J. K., Shin, J., Shin, H. J., Aslam, A., Kamaya, A., Rodgers, S. K., Sirlin, C. B., & Chernyak, V. (2025) · Radiology · doi:10.1148/radiol.240450 · Cited by 5
Surveillance for patients at risk of hepatocellular carcinoma: how to improve its cost-effectiveness and expand the role of multidisciplinary tumor board?
Lani, L., Zaccherini, G., Giannini, E. G., & Trevisani, F. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2024.136 · Cited by 5
Effectiveness of noncontrast-abbreviated magnetic resonance imaging in a real-world hepatocellular carcinoma surveillance
Yang, H. K., Lee, S., Lee, M. Y., & Kim, M. (2025) · European Radiology · doi:10.1007/s00330-025-11517-0 · Cited by 5
Investigating the molecular mechanisms and clinical potential of APO+ endothelial cells associated with PANoptosis in the tumor microenvironment of hepatocellular carcinoma using single-cell sequencing data
Cheng, Z., Yang, X., Ren, Y., Wang, H., Zhang, Q., Lin, S., Wu, W., Yang, X., Zheng, J., Liu, X., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102402 · Cited by 5
“Surgical intervention is the primary treatment for early-stage HCC, while immunotherapy is more commonly employed in advanced stages [3,4].”
Preoperative prediction of early recurrence in hepatocellular carcinoma using simultaneous multislice diffusion kurtosis imaging
Wu, Y., Ye, Z., Yang, T., Yao, S., Chen, J., Yin, T., & Song, B. (2025) · European Radiology · doi:10.1007/s00330-025-11633-x · Cited by 5
THE CONCEPT OF “CONVERSE THERAPEUTIC HIERARCHY” FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA
Vitale, A., Cabibbo, G., Rimassa, L., Iavarone, M. A., Colli, A., Crocetti, L., Pawlik, T. M., Gardini, A. C., Ponziani, F. R., Bargellini, I., et al. (2025) · Liver Cancer · doi:10.1159/000546360 · Cited by 5
“…available for patients with HCC, including liver transplantation (LT), liver resection (LR), thermal ablation (TA), external radiotherapy ablation, intra-arterial therapies (IAT) such as transarterial chemo-embolisation (TACE) or transarterial radio-embolisation, and systemic therapy (ST) [5, 6].”
Comparison of Surgical Resection and Radiofrequency Ablation for Early‐Stage HCC Patients With Child–Pugh Class B
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Kariyama, K., Itobayashi, E., Tsuji, K., Ishikawa, T., Toyoda, H., Koshiyama, Y., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17025 · Cited by 5
Imaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond
Haghshomar, M., Kierans, A. S., Kulik, L., Miller, F. H., & Borhani, A. A. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf123 · Cited by 5
Self-citation
Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis
Park, Y., Cho, Y., Kim, S. U., Kim, A., Shin, H., Kim, H., Lee, I. J., Kim, G. M., Hyun, D., Ko, Y., et al. (2025) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2025.09.002 · Cited by 5
Clinician Perspectives on Palliative Care for People with Hepatocellular Carcinoma: Facilitators of and Barriers to Referral
Woodrell, C. D., Mulholland, C. N., Goldstein, N. E., Hutchinson, C. L., Schiano, T. D., & Hansen, L. (2023) · Cancers · doi:10.3390/cancers15143617 · Cited by 5
“HCC is distinct from other types of solid cancer in terms of biology (frequent presence of concurrent cirrhosis), treatment modalities (systemic treatment is generally reserved for advanced disease), and a uniquely complex clinical landscape [9].”
Background
Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?
Jeepalyam, S., Sheel, A., Ejaz, A. M., Miller, E. D., & Manne, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814231 · Cited by 5
Blood-Based Biomarkers for HCC Surveillance: Ready for the Center Stage?
Singal, A. G., Yang, J. D., & Parikh, N. D. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002539 · Cited by 5
Self-citation
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study
Moon, A. M., Cook, S., Swier, R. M., Sanoff, H. K., Kappelman, M. D., Wagner, L. I., Barritt, A. S., Singal, A. G., Shah, N., Mauro, D. M., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000315 · Cited by 5
“Inclusion criteria were: age ≥ 18 years, HCC diagnosis based on American Association for the Study of Liver Diseases criteria, [23] plan to receive thermal ablation, TACE, TARE or SBRT, and English-speaking.”
MethodSelf-citation
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
Huang, C., Liang, P., Wang, C., Jang, T., Hsu, P., Tsai, P., Wei, Y., Yeh, M., Hsieh, M., Lin, Y., et al. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12804 · Cited by 5
Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab
Unome, S., Imai, K., Miwa, T., Hanai, T., Suetsugu, A., Takai, K., Suzui, N., Miyazaki, T., & Shimizu, M. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3071-23 · Cited by 5
“In this case, based on the elevated AFP levels, we considered the HCC component to be dominant and administered Dur/Tre as first-line treatment for unresectable HCC (27).”
Method
Detection of hepatocellular carcinoma methylation markers in salivary DNA
Mezzacappa, C., Wang, Z., Lu, L., Risch, H. A., Taddei, T. H., & Yu, H. (2024) · Bioscience Reports · doi:10.1042/bsr20232063 · Cited by 5
Self-citation
Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study
Singal, A. G., Parikh, N. D., Shetty, K., Han, S. B., Xie, C., Ning, J., Rinaudo, J. A., Arvind, A., Lok, A. S.-F., Kanwal, F., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002827 · Cited by 5
“…stage, societal guidelines from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver recommend ultrasound-based surveillance in at-risk patients including patients with cirrhosis or chronic hepatitis B virus (HBV) infection (5,6).”
Self-citation
Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine
Younis, M. A., & Harashima, H. (2024) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s431346 · Cited by 7
Liver resection had better disease-free survival rates compared with radiofrequency ablation in hepatocellular carcinoma: a meta-analysis based on randomized clinical trials
Yeo, Y. H., Kang, Y., Chen, C., Lee, T., Yeh, C.-C., Huang, T., & Wu, C.-Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001943 · Cited by 5
Interpretation of the updates of the chinese guidelines for the diagnosis and treatment of primary liver cancer (CNLC-2024 Edition)
Su, H., Wei, Y., Liao, X., Zhu, G., Peng, M., Fan, F., & Peng, T. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.70 · Cited by 5
Impact of Type of Lenvatinib Resistance on Prognosis and Second-Line Regimen in Patients with Virus-Associated HCC
Zhang, Y., Jin, L., Ma, H., & Zuo, S. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s476439 · Cited by 5
“6 To prolong the survival of HCC patients the clarification of the 2nd line treatment regimen after the occurrence of resistance to lenvatinib is extremely urgent.”
Background
Impact of pre-sarcopenia on outcomes of transarterial chemoembolization in unresectable hepatocellular carcinoma
Rattanasupar, A., Prateepchaiboon, T., Akarapatima, K., Songjamrat, A., Pakdeejit, S., & Chang, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-70266-0 · Cited by 5
Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort Study
Abdelmalak, J., Strasser, S. I., Ngu, N. L., Dennis, C. V., Sinclair, M. J., Majumdar, A., Collins, K., Bateman, K., Dev, A. T., Abasszade, J. H., et al. (2024) · Cancers · doi:10.3390/cancers16173010 · Cited by 5
Efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in hepatocellular carcinoma with macrovascular invasion: a single-center retrospective analysis
Ye, C., Ou, M., Zhang, W., Xu, B., Lu, T., Guo, Y., & Sun, X. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03538-8 · Cited by 5
“Traditionally, primary liver cancer with macrovascular invasion has been classified as advanced hepatocellular carcinoma (HCC), which carries a poor prognosis, and systemic palliative treatment has been considered the sole therapeutic option [3].”
Background
Machine Learning Model Based on Prognostic Nutritional Index for Predicting Long‐Term Outcomes in Patients With HCC Undergoing Ablation
Zhang, N., Lin, K., Qiao, B., Yan, L., Jin, D., Yang, D., Yang, Y., Xie, X., Xie, X., & Zhuang, B. (2024) · Cancer Medicine · doi:10.1002/cam4.70344 · Cited by 5
Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study
Lai, R., Barnett, S. D., Zhang, X., Kam, L. Y., Cheung, R. C., Xie, Q., & Nguyen, M. H. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004479 · Cited by 5
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma
Shiode, Y., Kodama, T., Sato, Y., Takahashi, R., Matsumae, T., Shirai, K., Doi, A., Tahata, Y., Hikita, H., Tatsumi, T., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00752-8 · Cited by 5
“AFP is the most widely used serum biomarker for HCC diagnosis and HCC surveillance using ultrasound and AFP at semiannual intervals is recommended in the American Association for the Study of Liver Diseases (AASLD) guideline [40].”

Authors: Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
Affiliations: The University of Texas Southwestern Medical Center (US)
Institució Catalana de Recerca i Estudis Avançats (ES)
Johns Hopkins University (US)
University of California, San Francisco (US)
Mayo Clinic (US)
University Health Network (CA)
Oregon Health & Science University (US)
Northwestern Medical Faculty Foundation (US)
University of California, Los Angeles (US)
University of Pennsylvania (US)
Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Vanderbilt University Medical Center (US)
Medical College of Wisconsin (US)
Stanford Medicine (US)
Memorial Sloan Kettering Cancer Center (US)
Yale University (US)
Corresponding author: Singal, Amit G.
ORCID: Singal, Amit G.
Llovet, Josep M.
Yarchoan, Mark
Mehta, Neil
Heimbach, Julie K.
Dawson, Laura A.
Jou, Janice H.
Kulik, Laura M.
Agopian, Vatche G.
Marrero, Jorge A.
Brown, Daniel B.
Goyal, Lipika
Wei, Alice C.
Taddei, Tamar H.
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2023-05-22
Volume: 78
Issue: 6
Pages: 1922-1965
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1097/hep.0000000000000466
PMC: PMC10663390
OpenAlex: W4377011124
Cited by: 2,052
References: 341
Citations by year: 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
FWCI: 346.25
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
American Association for the Study of Liver Diseases
Gilead Sciences
Boston Scientific Corporation
Exelixis
Incyte
Cancer Research UK (26813)
Eisai
Ipsen
Sirtex Medical
National Institutes of Health (UL1TR001863)
Genentech
National Cancer Institute (P50CA062924, R01CA285544)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords: hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
MeSH terms: Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks